Gain Therapeutics, Inc.
GANX
$1.72
-$0.11-6.01%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 16.64% | -23.60% | 14.13% | 9.03% | -28.23% |
| Total Depreciation and Amortization | 52.69% | -38.82% | 40.74% | 16.13% | -4.12% |
| Total Amortization of Deferred Charges | 8.33% | -7.69% | 8.33% | -7.69% | 18.18% |
| Total Other Non-Cash Items | 5.05% | 53.55% | -12.32% | -60.60% | 125.91% |
| Change in Net Operating Assets | -408.81% | 143.28% | -284.67% | 73.26% | -419.58% |
| Cash from Operations | 1.00% | -2.36% | 6.25% | 3.38% | -33.43% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 0.78% | -2.00% | 0.00% | -3.31% | -9.01% |
| Issuance of Common Stock | 223.73% | -97.41% | 122.40% | 199.22% | 2.96% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 100.00% | -- | -- |
| Cash from Financing | 237.89% | -97.56% | 135.34% | 185.11% | 2.90% |
| Foreign Exchange rate Adjustments | -675.61% | -74.85% | 1,359.70% | -97.42% | 137.53% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 19.61% | -135.73% | 469.33% | 189.08% | -80.41% |